Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pathogen Specific Immunity in Patients With Sarcoidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00217789
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : December 24, 2013
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey )

Brief Summary:
The purpose of this study is to assess the lung cells of healthy volunteers and patients with stage II and III pulmonary sarcoidosis for pathogen specific memory immunity and gene expression patterns.

Condition or disease Intervention/treatment
Sarcoidosis Procedure: Bronchoalveolar Lavage and Venipuncture

Detailed Description:

BACKGROUND:

Since its initial description 125 years ago, sarcoidosis continues to be a "challenging" disease. Its etiology remains unknown. Discovering the etiology of sarcoidosis remains a major goal with important implications regarding treatment, predicting outcome, as well as determining approaches for preventive measures. Immunological responses and granulomatous tissue formation characterizing sarcoidosis are similar to those observed in a variety of infectious diseases. However, the nature of the specific antigen(s), which putatively trigger the inflammatory response in sarcoidosis, remains elusive. Occurrence of sarcoidosis in spatially related clusters, and household and health care settings strongly support person-to-person transmission of an infectious agent as one of the potential causes of this disease. Sarcoidosis has been associated with a variety of infectious agents, none of which can be cultured. Propionibacterium acnes (P. acnes) and M.tuberculosis (Mtb) are the most commonly identifiable infectious pathogens by PCR-based methods and considered to be associated with the development of this disease. Immunological studies in sarcoidosis have focused largely on the assessment of constitutive, immune responses and the description of the phenotypes of blood and lung cells in patients and control subjects.

DESIGN NARRATIVE:

This study will utilize memory immune responses as search tools for the 'immunological imprints' from P. acnes or Mtb exposure. Peripheral blood mononuclear cells and bronchoalveolar cells will be compared from patients with stage II and/or stage III sarcoidosis and from healthy control subjects. Investigators will use ELISPOT assay to study: (1) frequencies of pathogen-specific interferon-7 and interleukin-10-producing cells, and (2) utilizing P. acnes- or Mtb-infected autologous monocytes and alveolar macrophages as target cell frequencies of pathogen-specific granzyme B-releasing cytotoxic T lymphocytes and natural killer cells. Finally, investigators will test the feasibility of identifying by DNA micro array, pathogen specific, transcriptional host gene expression profiles in P. acnes- and Mtb-stimulated blood cells from healthy control subjects and patients with active sarcoidosis and to compare these with gene expression profiles from autologous, unstimulated in situ lung cells. The studies will address the role of P. acnes and Mtb in the etiology of sarcoidosis and will also serve as a basis or model for future work involving other possible infectious or non-infectious pathogens/antigens for the development of sarcoidosis.

Layout table for study information
Study Type : Observational
Actual Enrollment : 5 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pathogen Specific Immunity in Sarcoidosis
Study Start Date : July 2004
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sarcoidosis




Primary Outcome Measures :
  1. Pathogen Specific Immunity in Sarcoidosis [ Time Frame: July 2004 - June 2008 ]
    Toxicity, DEP-Induced Cytokines, Effect of DEP on Stimulant-Induced Cytokine Production, in vitro Effects of DEP on M.tb-induced Cytokine Production, time kinetics of In vitro effects of DEP on M.tb-induced cytokine production, effect of DEP Exposure on M.tb H37Ra-induced Lymphocyte Proliferation, whole blood killing experiments



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Sarcoidosis patients and healthy subjects
Criteria

Inclusion Criteria for Sarcoidosis Participants:

  • Clinical and radiographic signs and symptoms consistent with pulmonary sarcoidosis stage II or III and confirmed histopathology
  • No prior corticosteroid or immune suppressive or immune modulating therapies

Inclusion Criteria for Healthy Participants:

  • No clinical and radiographic signs and symptoms of respiratory or other chronic or systemic illness

Exclusion Criteria for All Participants:

  • Unwilling or unable to provide informed consent
  • Unwilling or unable to comply with all study requirements
  • History of upper or lower respiratory tract infection within 1 month of study entry
  • History of major occupational or microbial exposures known to be associated with granulomatous inflammatory responses
  • Positive HIV-1 serology
  • Severe psychiatric disease
  • Cough-induced syncope
  • History of massive hemoptysis or history of pneumothorax, tuberculosis, and immunosuppressive therapies
  • Presence of any chronic medical condition requiring daily medication
  • Gingivitis or other infectious processes in the oral cavity
  • Positive skin test to purified protein derivative (tuberculin)
  • Hemoglobin level less than 10g/dl
  • Illicit drug use or history of cigarette smoking within 1 year prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00217789


Locations
Layout table for location information
United States, New Jersey
University of Medicine and Dentistry of New Jersey
Newark, New Jersey, United States, 07103
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Stephan Schwander, MD, PhD University of Medicine and Dentistry of New Jersey
Layout table for additonal information
Responsible Party: University of Medicine and Dentistry of New Jersey
ClinicalTrials.gov Identifier: NCT00217789    
Other Study ID Numbers: 0120040230; M-230-2004; 287
R21HL077462-02 ( U.S. NIH Grant/Contract )
R21HL077462 ( U.S. NIH Grant/Contract )
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: December 24, 2013
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoidosis
Lymphoproliferative Disorders
Lymphatic Diseases